(Date:12/11/2009)... Marrone Bio Innovations (MBI) today announces ... Mr. Chris Hildreth joined MBI as Senior Vice ... expanding all commercial aspects of the company, including ... Sing (Ray) Lam joined MBI as Vice President ... efforts in scaling its broad pipeline of products ...
(Date:12/11/2009)... Dec. 11 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, ... announced the appointment of Dr. Alan Warrander to ... and Business Development. ,, "Dr. Warrander will be ... strategy for REOLYSIN(R)," said Dr. Brad Thompson, President ... on the design of a Phase 3 trial ...
(Date:12/10/2009)... -- Dendreon Corporation (Nasdaq: DNDN ) announced today ... 15,000,000 shares of its common stock at a price ... also granted to the underwriters a 30-day option to ... stock to cover overallotments, if any. The offering ... to customary closing conditions. ,, J. P. Morgan Securities ...
(Date:12/10/2009)... Endologix, Inc. (Nasdaq: ELGX ), developer of ... that Dan Lemaitre, former President and CEO of ... effective December 11, 2009. Endologix now has ... Franklin D. Brown, Chairman of the Board, said, ... the Endologix Board of Directors. He has ...
Breaking Biology Technology:Marrone Bio Innovations Announces Two New Executive Appointments 2Marrone Bio Innovations Announces Two New Executive Appointments 3Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 3Dendreon Announces Pricing of Common Stock Offering 2Dendreon Announces Pricing of Common Stock Offering 3Endologix Appoints Dan Lemaitre to its Board of Directors 2(Date:12/15/2009)... Dec. 15 Rib-X Pharmaceuticals, Inc., a ... of novel drugs for the treatment of serious ... a collaborative research agreement with Massachusetts General Hospital ... for the collaboration, Dr. David Hooper of MGH ... established animal model to determine resistance development and ...
(Date:12/15/2009)... Dec. 15 Decision Resources, one of ... pharmaceutical and healthcare issues, finds that an overall ... for three-quarters of surveyed European oncologists in their ... Avastin for the treatment of breast cancer. ,, ... report entitled European Trends in Targeted Therapies ...
(Date:12/15/2009)... Inc., developer and marketer of the VerifyNow® System, ... measuring an individual,s response to multiple antiplatelet agents, ... number of international and U.S. distribution agreements, as ... capital financing that will take the company into ... its commitment to creating a powerful, worldwide distribution ...
Breaking Medicine Technology:Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital 2Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital 3For Breast Cancer Treatment, an Agent That Can Achieve an Overall Survival Benefit Would Pose the Greatest Challenge to Avastin's Dominance in Europe 2For Breast Cancer Treatment, an Agent That Can Achieve an Overall Survival Benefit Would Pose the Greatest Challenge to Avastin's Dominance in Europe 3Accumetrics Closes 2009 with Positive Outlook 2Accumetrics Closes 2009 with Positive Outlook 3A Public Option Means a Patient Option 54644 1Mothers Immune System May Block Fetal Treatments for Blood Diseases 54639 1Mothers Immune System May Block Fetal Treatments for Blood Diseases 54639 2Mothers Immune System May Block Fetal Treatments for Blood Diseases 54639 3Mothers Immune System May Block Fetal Treatments for Blood Diseases 54639 4Nucleix Researchers Discover DNA Evidence May Easily be Falsified 3A Company Develops New Detection Technology for Preventing Biological Identity The 13594 1Nucleix Researchers Discover DNA Evidence May Easily be Falsified 3A Company Develops New Detection Technology for Preventing Biological Identity The 13594 2Nucleix Researchers Discover DNA Evidence May Easily be Falsified 3A Company Develops New Detection Technology for Preventing Biological Identity The 13594 3Nucleix Researchers Discover DNA Evidence May Easily be Falsified 3A Company Develops New Detection Technology for Preventing Biological Identity The 13594 4